Zetia

Documents on the FDA Web site reveal that pharmaceutical companies Merck and Schering-Plough conducted numerous safety studies on the popular cholesterol drug Zetia but did not publish the results, which ...  

Schering-Plough Cut At Merrill, Vytorin/Zetia Concerns Cited  

Why is the editor of the New England Journal of Medicine encouraging a cancer scare over the cholesterol-lowering drug Vytorin? Is he overcompensating for past bad behavior?  

Currently, the Food and Drug Administration and the Congressional Energy and Commerce Committee are investigating the safety of both Vytorin and Zetia.  

Washington (dbTechno) - The safety of the Merck & Co and Schering-Plough cholesterol drug Vytorin has been put into question due to it being linked to deaths in patients. A new report published as an editorial in the New England Journal of Medicine has come out and questioned the safety of the...  

Researchers have discovered a reasonably widely used cholesterol drug can cause cancer. Or have they? A number of (mainly British) newspapers are convinced they have:Cholesterol lowering drug 'increases risk of cancer by 50 per cent' – Daily Telegraph Cholesterol pill warning: Scientists raise...  

Why is the editor of the New England Journal of Medicine encouraging a cancer scare over the cholesterol-lowering drug Vytorin? Is he overcompensating for past bad behavior? Prescribed for millions of patients, ...  

When the U.S. Food and Drug Administration (F.D.A.) approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no...  

More Treatment News September 26, 2008 Zetia may be an effective option for HIV-positive patients who had moderately elevated low-density lipoprotein levels - the "bad" form of cholesterol - and were on ...  

The Vytorin controversy is still hurting sales of the once-blockbuster cholesterol drug, with prescriptions down one-third this year.  To stem the bleeding, Schering-Plough, which markets Vytorin with Merck & Co., has announced that it will be eliminating 20 percent of its sales force.  The...  

Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of a leading medical journal urged yesterday.  

A cholesterol-lowering drug on the market for three decades has been found to lower the risk of diabetics losing a limb. A study of almost 10,000 type 2 diabetics over five years also revealed the drug fenofibrate reduced the need for laser therapy by as much as 49 per cent.  

Munich, Germany- When you get a large number of medical professionals at an international medical conference there are always differences of opinion, but none may be as strong as the current controversy about the cholesterol drug VyTorin. In one study that was first announced in July, the...  

CHOLESTEROL COUNT: Three studies of the cholesterol-lowering drug Vytorin, funded by its makers, can't prove or rule out a possible link to a higher risk of cancer that emerged this summer.  

Fears that a drug used to treat high cholesterol could cause cancer today led to heart experts calling for caution over its future use.